The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

Trump-Xi truce talks, Nvidia’s $5T milestone, Big Tech earnings, and Musk’s $1T showdown headline a packed week.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Pfizer is suing Metsera and Novo Nordisk over Novo's $9 billion bid to acquire Metsera, arguing significant regulatory risk ...

The top seven customers of the hard-drive company have provided purchase orders through at least the first half of next year. The company said it is on track to meet its advisor retention goals for ...

In a lawsuit filed in Delaware Chancery Court, Pfizer said Novo Nordisk’s offer can’t be considered superior because it isn’t ...

Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom.

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, claiming Metsera violated its merger agreement by entertaining Novo's superior bid offer. Pfizer seeks a court order to prevent Metsera ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based ...

Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are trading lower Friday morning, continuing an after-hours slide that began Thursday. The decline was sparked by comments from ...